Avidity Biosciences Inc
RNA
View Detailed Chart
72.900USD
+0.080+0.11%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
10.70BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.11%
5 Days
+0.45%
1 Month
+0.90%
6 Months
+51.06%
Year to Date
+1.07%
1 Year
+107.63%
View Detailed Chart
TradingKey Stock Score of Avidity Biosciences Inc
Currency: USD Updated: 2026-02-06Key Insights
Avidity Biosciences Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 56 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 72.62.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Avidity Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Avidity Biosciences Inc Highlights
StrengthsRisks
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 18.14% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 10.90M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 10.90M.
Undervalued
The company’s latest PE is -17.38, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 151.27M shares, decreasing 5.87% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 8.53K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.87.
Analyst Rating
Based on
14
analysts
Hold
Current Rating
72.615
Target Price
-0.28%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Avidity Biosciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Avidity Biosciences Inc Info
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
Ticker SymbolRNA
CompanyAvidity Biosciences Inc
CEOBoyce (Sarah)
Websitehttps://www.aviditybiosciences.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68938.180
-1031.950 (-1.47%)
282.580
+22.390 (+8.61%)
2033.920
-17.810 (-0.87%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
